04:55 AM EST, 01/31/2025 (MT Newswires) -- Vertex Pharmaceuticals ( VRTX ) said Friday it has made a reimbursement agreement with National Health Service England for eligible sickle cell disease patients to access the CRISPR/Cas9 gene-edited therapy, Casgevy.

The reimbursement agreement coincides with the UK National Institute for Health and Care Excellence recommending Casgevy's use by the NHS, the company said.

Administration of the therapy requires experience in stem cell transplantation, and Vertex said it is working with hospitals to establish treatment centers.

Shares of the company were up more than 8% in Friday's premarket activity.

Price: 475.00, Change: +36.60, Percent Change: +8.35